How to Invest in Biotech
Biotech can be the highest-return sector in your portfolio. It can also be the costliest if you don't know what you're doing. Here's the framework.
Start free with Clinical Investor âBiotech is one of the few sectors where individual stock picks can return 1000%+ â or go to zero in a single day. Successful biotech investors build a framework for evaluating science, managing position sizing, and timing around catalysts. Here's the playbook.
Build the right portfolio structure
- Position sizing matters more than picking. Limit any single biotech to 2-5% of portfolio. Even "sure things" go to zero.
- Hold 8-15 names. Fewer than 8 = single-stock risk dominates. More than 15 = you can't track the science.
- Mix stages. 30% commercial-stage (revenue, lower risk), 50% Phase 3 / NDA-stage (catalyst-driven), 20% Phase 2 (high upside).
- Set a per-trade max loss. If a stock drops 30% on bad data, sell â your thesis is broken. Don't average down.
How to actually evaluate a biotech stock
- Read the lead asset's clinical trial protocol. See how-to-read guide.
- Check the catalyst calendar for the next 12 months. Use Clinical Investor or BioPharma Catalyst.
- Evaluate the pipeline depth. One-product companies are binary bets; pipelines with 3+ Phase 2/3 assets reduce single-readout risk. See pipeline evaluation.
- Check cash runway. Find cash + cash equivalents in latest 10-Q; divide by quarterly burn rate. Less than 12 months = imminent dilution risk.
- Compare to comparable peers. Market cap relative to addressable market, peer-group P/sales for commercial stage, peer-group EV/pipeline-stage for clinical stage.
Risk management rules
- Never go to 100% biotech allocation; treat it as the high-risk slice of a diversified portfolio
- Avoid OTC-traded micro-cap biotechs unless you can do primary diligence (most are pumps)
- Avoid using margin or options on a biotech you don't understand
- If a CEO is pumping the stock on Twitter or doing reverse splits to maintain listing â that's a red flag, not a buying opportunity
- Sell into binary catalyst run-ups if your thesis was already partially priced in
What to avoid
- "Story stocks" with no Phase 2 data and no Phase 3 plans
- Companies that have done multiple reverse splits
- Companies whose only "catalyst" is hype around a partnership announcement
- Indication-specific companies with no plan B if the lead indication fails
Get the catalyst calendar + Trial Translator
Free tier: weekly catalyst briefing, basic company profiles. Premium ($19/mo): real-time alerts, unlimited Trial Translator, deep dives.
Start free âFrequently Asked Questions
- How much money do I need to start investing in biotech?
- You can start with any amount, but to build a diversified 8-15 name portfolio, $5,000-$10,000 minimum is practical. Below that, you're forced to concentrate.
- Can I just buy a biotech ETF?
- Yes â XBI (S&P Biotech) and IBB (NASDAQ Biotech) give broad exposure. Trade-off: you don't capture the asymmetric upside of individual catalyst hits, but you avoid single-stock blowups. Many investors hold both an ETF base + concentrated single-name positions.
- How do I know when to sell?
- Sell when (a) the catalyst plays out as priced in, (b) the thesis breaks (negative data, failed trial, change in management), (c) the position grew too large and threatens portfolio risk limits.
- Are biotech IPOs worth investing in?
- Sometimes â but most biotech IPOs underperform in the first year as lockup expiration creates supply pressure. Full guide on biotech IPOs.
Related guides
Educational only. Not investment advice. Biotech investing carries substantial risk; consult a licensed advisor.